At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Market Closed 04-04 16:00:00 EDT
1.51
+0.07
+4.86%
盘后1.53
+0.02+1.32%
19:59 EDT
| High1.70 | Low1.21 | Vol866.84K |
| Open1.35 | D1 Closing1.44 | Amplitude34.03% |
| Mkt Cap2.89M | Tradable Cap792.60K | Total Shares1.91M |
| T/O1.26M | T/O Rate165.14% | Tradable Shares524.90K |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Philip Morris International Releases Integrated Report Detailing Progress Towards Its Smoke-Free Vision
Business Wire · 04-03 08:30
BRIEF-Gri Bio Announces Closing Of $5.0 Million Public Offering
Reuters · 04-02
GRI Bio Announces Closing of $5.0 Million Public Offering
THOMSON REUTERS · 04-02
GRI Bio Shares Jump After Drug-Trial Update, Hit 52-Week Low After Offering News
Dow Jones · 04-01
GRI Bio Prices up to $13 Million Equity Offering
MT Newswires Live · 04-01
GRI Bio Announces Pricing of $5.0 Million Public Offering
THOMSON REUTERS · 04-01
GRI Bio Announces Pricing of $5.0 Million Public Offering
GlobeNewswire · 04-01
BRIEF-Gri Bio Inc - IDMC Recommends Continuation Of Study With No Safety Concerns
Reuters · 04-01
GRI Bio Inc - Interim Biomarker Data Expected Q2 2025, Topline Results Q3 2025
THOMSON REUTERS · 04-01
GRI Bio Reports Encouraging Interim 2-Week Safety Results From Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“Ipf”)
THOMSON REUTERS · 04-01
GRI Bio Inc - GRI-0621 Safe and Well-Tolerated in First 12 Patients
THOMSON REUTERS · 04-01
GRI Bio Inc - Idmc Recommends Continuation of Study With No Safety Concerns
THOMSON REUTERS · 04-01
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire · 04-01
GRI Bio Bolsters Intellectual Property Portfolio With Granting of Two Global Patents for Europe and Japan
THOMSON REUTERS · 03-31
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
GlobeNewswire · 03-31
DuPont Earns Silver Medal from EcoVadis for Sustainability Performance
PR Newswire · 03-27
Teck Reports 2024 Sustainability Performance
GlobeNewswire · 03-21
GRI Bio Participates in a Virtual Investor CEO Connect Segment
GlobeNewswire · 03-18
McEwen Mining Reports 2024 Q4 & Year-End Results and Outlook for 2025
GlobeNewswire · 03-18
GRI Bio Reports As Of December 31, 2024, The Company Had Cash And Cash Equivalents Of ~$5M; Cash Runway Expected To Fund Operations Into Q2 2025, Including Interim Data Readout From GRI-0621
Benzinga · 03-17
Introduction
Company Name.
GRI BIO INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App